ArticleUrologic oncology2018
Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer.
Article in Urologic oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Racial and ethnic differences in bladder cancer diagnosis, treatment, and specialty care access amongFrontiers in oncology · 2026Article
- Article
- Existing Health Inequities in the Treatment of Advanced and Metastatic Cancers.Current oncology reports · 2024Review
- Mevalonate pathway inhibition reduces bladder cancer metastasis by modulating RhoB protein stability and integrin β1 localization.Communications biology · 2024Article
- NCellular & molecular biology letters · 2024Article
- Regional differences in metastatic urothelial carcinoma of the urinary bladder patients across the United States SEER registries.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Article
- A model established using marital status and other factors from the Surveillance, Epidemiology, and End Results database for early stage gastric cancer.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2022Article
- Prognostic Factors for Bladder Cancer Patients in Malaysia: A Population-Based Study.International journal of environmental research and public health · 2022Article
- Gender dimorphism in survival of patients with lymph node metastasis of bladder cancer.Therapeutic advances in medical oncology · 2022Article
- Efficacy of chemotherapy on overall survival in metastatic sarcomatoid bladder cancer patients.Central European journal of urology · 2022Article
- The association of health insurance with the survival of cancer patients with brain metastases at diagnosis.Technical innovations & patient support in radiation oncology · 2021Article
- Systematic review of the association between socioeconomic status and bladder cancer survival with hospital type, comorbidities, and treatment delay as mediators.BJUI compass · 2021Review
- Survival rate of patients with bladder cancer and its related factors in Kurdistan Province (2013-2018): a population-based study.BMC urology · 2020Article
- A mediation analysis to explain socio-economic differences in bladder cancer survival.Cancer medicine · 2020Article
- Clinicopathological characteristics and treatment outcomes of 162 Chinese patients with metastatic bladder cancer: results from a tertiary teaching hospital.Translational cancer research · 2020Article
- Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options.The Korean journal of internal medicine · 2020Review
- Outcomes of upper tract urothelial carcinoma with isolated lymph node involvement following surgical resection: implications for multi-modal management.World journal of urology · 2020Article
- Marital Status and Prognostic Nomogram for Bladder Cancer With Distant Metastasis: A SEER-Based Study.Frontiers in oncology · 2020Article
- Racial and Socioeconomic Disparities in Bladder Cancer Survival: Analysis of the California Cancer Registry.Clinical genitourinary cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTo evaluate how socioeconomic status and other demographic factors are associated with the receipt of chemotherapy and subsequent survival in patients diagnosed with metastatic bladder cancer.
methodsUsing data from the California Cancer Registry, we identified 3,667 patients diagnosed with metastatic urothelial carcinoma of the urinary bladder between 1988 and 2014. The characteristics of patients who did and did not receive chemotherapy as part of the first course of treatment were compared using chi-square tests. Logistic regression was used to identify predictors of chemotherapy treatment. Fine and Gray competing-risks regression and Cox proportional hazards regression were used to estimate bladder cancer-specific and all-cause mortality, respectively.
resultsLess than half (46.3%) of patients received chemotherapy. Patients from the lowest socioeconomic quintile were half as likely to have chemotherapy as those from highest quintile (odds ratio = 0.5, 95% CI: 0.4, 0.7). Unmarried patients were significantly less likely to receive treatment (odds ratio = 0.6, 95% CI: 0.5, 0.7). Not receiving chemotherapy was associated with greater mortality from bladder cancer (subdistribution hazard ratio = 1.4, 95% CI: 1.3, 1.5) and from all causes (hazard ratio = 2.0, 95% CI: 1.8, 2.1).
conclusionsWe found clear disparities in chemotherapy treatment and survival with respect to socioeconomic and marital status. Future studies should explore the possible reasons why patients with low socioeconomic status and who are unmarried are less likely to have chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.